6328-94-5

Usage

Uses

Used in Pharmaceutical Development:
CHEMBRDG-BB 7356177 is used as a potential drug candidate for the development of new therapeutic agents. Its biological and pharmacological properties are currently under investigation to determine its efficacy and safety in treating various diseases and conditions.
Used in Research and Testing:
CHEMBRDG-BB 7356177 is utilized in research and testing to explore its interactions with biological targets and receptors. This helps in understanding its potential applications in drug development and therapeutic interventions.
Used in Drug Discovery:
CHEMBRDG-BB 7356177 is employed in drug discovery processes to identify its potential as a lead compound for the development of novel drugs. Its unique properties and interactions with biological systems make it a promising candidate for further exploration and optimization.
Used in Chemical Synthesis:
CHEMBRDG-BB 7356177 may be used as a starting material or intermediate in the synthesis of other chemical compounds with potential applications in various industries, including pharmaceuticals, materials science, and agrochemicals.

InChI:InChI=1/C11H13NO3/c1-2-5-10(13)12-9-7-4-3-6-8(9)11(14)15/h3-4,6-7H,2,5H2,1H3,(H,12,13)(H,14,15)

Upstream product

• 106-31-0 butanoic acid anhydride 
• 118-92-3 anthranilic acid 
• 141-75-3 butyryl chloride 
• 107-92-6 butyric acid 
• 68-12-2 N,N-dimethyl-formamide 
• 91-56-5 indole-2,3-dione 
• 92675-59-7 1-Butyryl-1H-indole-2,3-dione 
• 33913-15-4 N-o-tolylbutyramide 

Downstream Products

• 297762-40-4 3-<4-Methoxy-phenyl>-2-propyl-3H-chinazol-4-on 
• 1293362-89-6 3-(3-hydroxyphenyl)-2-propylquinazolin-4(3H)-one 
• 1293363-13-9 3-(phenylamino)-2-propylquinazolin-4(3H)-one 
• 1293363-05-9 2-{1-{[(4-dimethylamino)phenyl]methylidene}propyl}-3-hydroxyquinazolin-4(3H)-one 
• 1293363-04-8 2-{1-[(3,4-dimethoxyphenyl)methylidene]propyl}-3-hydroxyquinazolin-4(3H)-one 
• 1293362-99-8 4-[4-oxo-2-propylquinazolin-3(4H)-yl]-N-(thiazol-2-yl)benzenesulfonamide 
• 1293362-97-6 N-(5-methylisoxazol-3-yl)-4-[4-oxo-2-propylquinazolin-3(4H)-yl]benzenesulfonamide 
• 1293362-96-5 4-{2-{1-[(1,3-benzodioxol-5-yl)methylidene]propyl}-4-oxoquinazolin-3(4H)-yl}benzoic acid 
• 1293362-95-4 4-{2-{1-{[(4-dimethylamino)phenyl]methylidene}propyl}-4-oxoquinazolin-3(4H)-yl}benzoic acid 
• 1293362-94-3 4-{2-{1-[(3,4-dimethoxyphenyl)methylidene]propyl}-4-oxoquinazolin-3(4H)-yl}benzoic acid 
• 1293410-53-3 3-(((E)-[4-(4-chloro-3-methylphenoxy)phenyl]methylidene)amino)-2-propylquinazolin-4(3H)-one 
• 1293410-52-2 3-(((E)-[4-(4-fluorophenoxy)phenyl]methylidene)amino)-2-propylquinazolin-4(3H)-one 
• 1293410-51-1 3-(((E)-[4-(4-bromophenoxy)phenyl]methylidene)amino)-2-propylquinazolin-4(3H)-one 
• 1293410-50-0 3-(((E)-[4-(4-chlorophenoxy)phenyl]methylidene)amino)-2-propylquinazolin-4(3H)-one 

Relevant academic research and scientific papers

Silver-Mediated Synthesis of 4H-Benzoxazin-4-ones by Intramolecular Decarboxylative O-Acylation Reactions with α-Oxocarboxylic Acid

The first example of an intramolecular decarboxylative acylation reaction for the synthesis of 4H-benzoxazin-4-one derivatives has been described. The silver-mediated reaction has a broad substrate scope and provides a mild and rapid approach to the corre

Synthesis of a novel series of 2,3-disubstituted quinazolin-4(3H)-ones as a product of a nucleophilic attack at C(2) of the corresponding 4H-3,1-benzoxazin-4-one

A new series of 2,3-disubstituted quinazolin-4(3H)-one derivatives was synthesized by nucleophilic attack at C(2) of the corresponding key starting material 2-propyl-4H-3,1-benzoxazin-4-one (Scheme 2). The reaction proceeded via amidinium salt formation (Scheme 3) rather than via an N-acylanthranilimide. The structure of the prepared compounds were elucidated by physical and spectral data like FTIR, 1H-NMR, and mass spectroscopy.

Design, synthesis and potential 6 Hz psychomotor seizure test activity of some novel 2-(substituted)-3-{[substituted]amino}quinazolin-4(3H)-one

Thirty new 2-(substituted)-3-{[substituted]amino}quinazolin-4(3H)-one were designed and synthesized keeping in view the structural requirement of pharmacophore and evaluated for anticonvulsant activity and neurotoxicity. The anticonvulsant activity of the titled compounds was assessed using the 6 Hz psychomotor seizure test. The most active compound of the series was 3-({(E)-[3-(4-chloro-3-methylphenoxy)phenyl]methylidene}amino) -2-phenylquinazolin-4(3H)-one PhQZ 7, which showed 100% protection (4/4, 0.5 h) and 75% protection (3/4, 0.25 h) at a dose of 100 mg/kg in mice. A computational study was carried out for calculation of pharmacophore pattern and prediction of pharmacokinetic properties. Titled compounds have also exhibited good binding properties with epilepsy molecular targets such as glutamate, GABA (A) delta and GABA (A) alpha-1 receptors, in Lamarckian genetic algorithm based flexible docking studies.

Synthesis and biological evaluation of some new 4(3H)-quinazolinone derivatives as non-classical antifolate

LL living cell need tetrahydrofolate cofactor for the synthesis of purines, some amino acid and thymidine. Most bacteria and plant produce this folate cofactor by de novo biosynthesis. Compounds that interfere with this pathway, antifolate agents have found use as anticancer. Thus, the 2-propyl-4H-3,1- benzoxazin-4-one (2) was synthesized and allowed to interaction with Ammonium acetate or formamide afforded-2-propylquinazolin-4(3H)-one (3). Behaviour of quinazolinone towards carbon electrophiles namely, aromatic aldehyde, chloroacetylchloride, and ethylchloroacetate has been investigated and all the synthesized compounds were tested as anti-cancer in National Cancer Institute (NCI) in USA.

Methods and compositions utilizing quinazolinones

Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.

Process for the racemization of chiral quinazolinones

Racemates are obtained from one of the enantiomers, or an enantiomerically enriched mixture, of an optically active quinazolinone derivative by reaction of the compound with an alkali alkoxide of a primary alcohol and isolation of the racemate.

Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds

A 4-centre PDE 4 pharmacophore search has been carried out in several 3D-databases containing compounds belonging to different therapeutic areas. Losartan, an angiotensin-II antagonist, has been identified as a new lead compound for developing PDE 4 inhibitors. New families of compounds derived from losartan has been synthesized and their PDE inhibition has been measured.